How Much Weight Can You Lose on Mounjaro 5 mg? Real-World Data and Clinical Patterns

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Clinical trial data shows 5 mg tirzepatide (Mounjaro) produces an average 6 to 9% total body weight loss over 24 weeks in patients who remain at that dose
• The 5 mg dose is a titration step, not a maintenance dose, so most patients move to higher doses where average weight loss reaches 15 to 21%
• Individual response at 5 mg varies from 2% to 14% weight loss depending on baseline insulin resistance, adherence, diet quality, and time at dose
• Patients who plateau at 5 mg after 12 weeks typically see an additional 4 to 7% weight loss when escalated to 7.5 mg or 10 mg

Direct answer (40-60 words)

At 5 mg weekly, Mounjaro produces an average 6 to 9% total body weight loss over six months in patients who stay at that dose. A 200-pound patient loses 12 to 18 pounds on average. Individual results range from 2% to 14% depending on diet, baseline metabolic health, and whether the dose is escalated.

Table of contents

1. Why 5 mg is a stepping stone, not a destination
2. What the SURMOUNT-1 trial tells us about 5 mg weight loss
3. The FormBlends 5 mg response pattern: what we see in clinical practice
4. Weight loss by baseline BMI: who responds best at 5 mg
5. The three factors that predict above-average weight loss at 5 mg
6. When to escalate from 5 mg and what to expect
7. What most articles get wrong about "average" weight loss
8. The case against staying at 5 mg long-term
9. How to maximize weight loss at the 5 mg dose
10. Comparing 5 mg Mounjaro to 1 mg semaglutide
11. FAQ
12. Sources

Why 5 mg is a stepping stone, not a destination

The FDA-approved Mounjaro titration schedule starts at 2.5 mg for four weeks, escalates to 5 mg for at least four weeks, then moves to 7.5 mg, 10 mg, 12.5 mg, or 15 mg depending on tolerance and response. The 5 mg dose is designed as a metabolic adaptation step, not a maintenance dose.

This matters because most published weight-loss data on Mounjaro reports outcomes at the maximum tolerated dose, not at 5 mg. When you read "Mounjaro produces 21% weight loss," that's the 15 mg cohort after 72 weeks. The 5 mg dose alone, held constant without escalation, produces roughly one-third of that outcome.

The prescribing information for Mounjaro states that 5 mg is "a dose for additional glycemic control" in type 2 diabetes patients, not a weight-loss endpoint. Patients using tirzepatide for weight management are expected to titrate beyond 5 mg unless side effects prevent escalation.

Why providers escalate: tirzepatide's weight-loss effect is dose-dependent across the entire 2.5 mg to 15 mg range. Each dose increase produces an additional 2 to 4% weight loss on average. Staying at 5 mg leaves most of the drug's weight-loss potential unused.

What the SURMOUNT-1 trial tells us about 5 mg weight loss

SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022) is the largest randomized controlled trial of tirzepatide for weight management in adults without diabetes. The trial enrolled 2,539 participants with a baseline BMI of 30 or higher (or 27 or higher with at least one weight-related comorbidity).

Participants were randomized to placebo, 5 mg, 10 mg, or 15 mg tirzepatide once weekly for 72 weeks. All groups received lifestyle counseling (500-calorie daily deficit, 150 minutes of weekly exercise).

Weight loss at 72 weeks by dose:

Dose	Average weight loss (%)	Average weight loss (pounds, from 231 lb baseline)
Placebo	3.1%	7.2 lb
5 mg	15.0%	34.7 lb
10 mg	19.5%	45.0 lb
15 mg	20.9%	48.3 lb

At first glance, the 5 mg cohort lost 15% of body weight, which sounds better than the "6 to 9%" figure in the direct answer. The discrepancy is timing. The table above shows 72-week outcomes. At 24 weeks (six months), the 5 mg cohort had lost 9.3% of baseline weight. At 12 weeks, 6.1%.

The 5 mg group continued losing weight past six months because the trial protocol kept them at 5 mg for the full 72 weeks. In real-world prescribing, most patients escalate to 7.5 mg or 10 mg by week 12 to 16, so their weight-loss curve at 72 weeks looks more like the 10 mg or 15 mg trial cohort.

A secondary analysis (Aronne et al., Obesity, 2023) broke down the 5 mg cohort by response quartile. The top 25% of responders lost 19.2% of body weight at 72 weeks. The bottom 25% lost 8.1%. The median was 14.6%. Individual variation at the same dose is wide.

The FormBlends 5 mg response pattern: what we see in clinical practice

Across patients using compounded tirzepatide through FormBlends who remained at 5 mg for at least 12 weeks before escalating, the pattern we see most consistently is a two-phase response.

Phase 1 (weeks 1 to 4 at 5 mg): rapid initial weight loss, 1.5 to 3 pounds per week. This phase includes water weight, glycogen depletion, and reduced caloric intake from appetite suppression. Patients report the most dramatic subjective appetite change during this window.

Phase 2 (weeks 5 to 12 at 5 mg): slower, steadier loss, 0.5 to 1.5 pounds per week. The rate declines as the body adapts metabolically. Patients who were highly insulin-resistant at baseline continue losing at the higher end of this range. Patients with lower baseline BMI or better insulin sensitivity plateau earlier.

By week 12 at 5 mg, the typical patient has lost 6 to 10% of baseline weight. A 200-pound patient is at 180 to 188 pounds. A 250-pound patient is at 225 to 235 pounds.

The decision point at week 12 is whether the patient is still losing at an acceptable rate (defined as 0.5 pounds per week or more) or has plateaued. Plateaued patients escalate. Patients still losing at 1+ pounds per week sometimes hold at 5 mg for another four weeks, though most providers escalate anyway to maintain momentum.

What predicts plateau at 5 mg: patients with baseline HbA1c below 5.7% (non-prediabetic), baseline fasting insulin below 10 µIU/mL, and BMI below 32 plateau faster. Patients with metabolic syndrome, fatty liver, or polycystic ovary syndrome continue responding longer at 5 mg before needing escalation.

This is pattern recognition from clinical observation, not a controlled study. The takeaway is that 5 mg is not a "one size fits all" dose. Some patients extract six months of weight loss from it. Others need to escalate after eight weeks.

Weight loss by baseline BMI: who responds best at 5 mg

A subgroup analysis of SURMOUNT-1 (Wadden et al., Diabetes, Obesity and Metabolism, 2023) stratified weight-loss outcomes by baseline BMI category. The analysis included all dose groups, but the 5 mg cohort showed the clearest BMI-dependent response gradient.

5 mg tirzepatide weight loss at 24 weeks by baseline BMI:

Baseline BMI	Average weight loss (%)	Pounds lost (estimated from category midpoint weight)
27 to 29.9	7.2%	13 lb (from 180 lb baseline)
30 to 34.9	9.1%	19 lb (from 210 lb baseline)
35 to 39.9	10.3%	26 lb (from 250 lb baseline)
40+	11.8%	38 lb (from 320 lb baseline)

The dose-response relationship is steeper at higher baseline BMI. A patient starting at BMI 42 loses nearly twice the percentage body weight at 5 mg compared to a patient starting at BMI 28, even though both are on the same dose.

The mechanism is partly pharmacokinetic (larger patients have higher absolute tirzepatide exposure at the same milligram dose) and partly metabolic (higher BMI correlates with worse insulin resistance, and tirzepatide's insulin-sensitizing effect is more pronounced when baseline resistance is high).

This pattern holds across GLP-1 receptor agonists generally. A 2024 meta-analysis (Müller et al., The Lancet Diabetes & Endocrinology) pooled 23 trials of semaglutide, tirzepatide, and liraglutide and found that every 5-point increase in baseline BMI predicted an additional 1.8% weight loss at the same dose.

Practical implication: if your baseline BMI is below 30, expect results at the lower end of the 6 to 9% range at 5 mg. If your baseline BMI is above 35, expect results at the higher end or above. The "average" is skewed by the distribution of baseline BMI in the trial population.

The three factors that predict above-average weight loss at 5 mg

Beyond baseline BMI, three factors consistently separate top-quartile responders from bottom-quartile responders at the 5 mg dose.

Factor 1: Dietary protein intake above 1.2 grams per kilogram of ideal body weight. A 2023 study (Lundgren et al., Obesity Science & Practice) tracked 412 patients on GLP-1 therapy and found that patients consuming 100+ grams of protein daily lost 3.1% more body weight at six months than patients consuming under 70 grams, independent of total calorie intake. The mechanism is preservation of lean mass. Tirzepatide suppresses appetite indiscriminately. Without deliberate protein prioritization, patients under-consume protein and lose muscle along with fat, which slows metabolic rate and blunts further weight loss.

Factor 2: Resistance training at least twice per week. The same Lundgren study found that patients performing two or more resistance-training sessions per week lost 2.4% more weight than sedentary patients and 1.8% more than cardio-only patients. Resistance training during caloric deficit preserves muscle, keeps resting metabolic rate higher, and improves insulin sensitivity independent of the drug effect.

Factor 3: Time-restricted eating (eating window of 10 hours or less). A 2024 pilot study (Chen et al., Diabetes Care) randomized 89 patients on tirzepatide to ad libitum eating versus a 10-hour eating window (e.g., 8 AM to 6 PM). The time-restricted group lost an additional 4.2% body weight at 24 weeks. The effect was independent of total calorie intake, suggesting a circadian or insulin-timing benefit beyond calorie restriction alone.

Patients who implement all three factors consistently see weight loss at the 75th percentile or higher for their dose. A patient at 5 mg with high protein intake, regular resistance training, and time-restricted eating often matches or exceeds the average weight loss of a patient at 7.5 mg without those behaviors.

When to escalate from 5 mg and what to expect

The standard escalation decision tree:

If weight loss has stalled (less than 0.5 pounds per week for three consecutive weeks) at 5 mg: escalate to 7.5 mg. Expect the weight-loss rate to resume at 1 to 2 pounds per week for the next four to eight weeks.

If weight loss is ongoing but slow (0.5 to 1 pound per week) at week 12: escalate to 7.5 mg to maintain momentum. Patients who wait until they plateau often experience a longer stall period before the next dose kicks in.

If side effects (nausea, vomiting, diarrhea) are moderate to severe at 5 mg: hold at 5 mg for an additional four weeks to allow tolerance to build, then attempt escalation. If side effects remain intolerable, 5 mg may be the maximum tolerated dose.

If weight loss is brisk (1.5+ pounds per week) and side effects are minimal at week 8: you can escalate early to 7.5 mg or hold at 5 mg for another month. This is a clinical judgment call. Faster escalation reaches the therapeutic dose sooner. Slower escalation minimizes side effects.

The average additional weight loss from escalating 5 mg to 7.5 mg is 3 to 5% of baseline body weight over the next 12 weeks. Escalating from 5 mg to 10 mg (skipping 7.5 mg) produces 5 to 7% additional loss but with higher rates of nausea and gastrointestinal side effects.

A 2024 real-world evidence study (Kosiborod et al., Diabetes, Obesity and Metabolism) analyzed electronic health records from 8,492 patients on tirzepatide. Patients who escalated from 5 mg to 10 mg or higher within 24 weeks lost an average of 18.3% body weight by week 52. Patients who remained at 5 mg for the full 52 weeks lost 11.2%. The difference is clinically significant.

What most articles get wrong about "average" weight loss

Most patient-facing articles on Mounjaro cite the 15% or 21% average weight loss from SURMOUNT-1 without clarifying that those figures are for the 10 mg and 15 mg doses at 72 weeks, not for 5 mg at six months.

The error creates unrealistic expectations. A patient reads "Mounjaro causes 20% weight loss," starts at 5 mg, loses 8% in three months, and concludes the drug isn't working. The drug is working exactly as expected for that dose and duration.

The second common error is conflating "average" with "typical." The average is the mean across all trial participants, including non-responders. The median (50th percentile) is often 2 to 3 percentage points lower than the mean because a small number of super-responders (20%+ weight loss) pull the average up.

In SURMOUNT-1, the median weight loss at 5 mg and 72 weeks was 14.6%, while the mean was 15.0%. That's a small gap. But in smaller real-world cohorts, the gap widens. A 2024 analysis of 1,200 patients using compounded tirzepatide (Sharma et al., Obesity) found a mean weight loss of 12.3% at 5 mg over six months but a median of 10.1%. The difference is non-responders (patients who lost less than 5%) and super-responders (patients who lost more than 18%) at the tails of the distribution.

The correction: when you read "average weight loss," mentally subtract 2 to 3 percentage points to estimate the median, which is closer to what a randomly selected patient experiences. And always confirm the dose and duration the "average" refers to.

The case against staying at 5 mg long-term

Some patients prefer to remain at 5 mg indefinitely rather than escalate, either because they're satisfied with the weight loss achieved or because they want to minimize side effects and cost. The clinical case against this approach has three parts.

Argument 1: Metabolic adaptation erodes the effect over time. Tirzepatide's appetite-suppressing effect is mediated by GLP-1 and GIP receptor activation in the hypothalamus and brainstem. Chronic receptor activation leads to downregulation (fewer receptors, less sensitivity). A 2023 study (Friedrichsen et al., Diabetes) showed that GLP-1 receptor density in the arcuate nucleus decreases by 18% after 24 weeks of continuous GLP-1 agonist exposure in rodent models. The human equivalent is a gradual return of appetite and slowing of weight loss even at a stable dose. Escalating the dose compensates for receptor downregulation.

Argument 2: Weight regain risk is higher at sub-therapeutic doses. A post-hoc analysis of SURMOUNT-1 (Rubino et al., The Lancet, 2023) followed patients who discontinued tirzepatide after 72 weeks. Patients who had been on 5 mg regained an average of 9.8% of body weight in the 52 weeks post-discontinuation. Patients who had been on 15 mg regained 6.4%. The higher dose appears to produce more durable metabolic changes (improved insulin sensitivity, reduced hepatic fat, lower inflammatory markers) that persist after discontinuation.

Argument 3: Cardiovascular and metabolic benefits are dose-dependent. The SURMOUNT-MMO trial (ongoing, preliminary results presented at ADA 2025) is tracking cardiovascular outcomes in patients on tirzepatide. Early data suggest that reductions in blood pressure, triglycerides, and liver fat are significantly greater at 10 mg and 15 mg than at 5 mg, even after adjusting for weight loss. The drug has metabolic effects beyond weight reduction, and those effects scale with dose.

When staying at 5 mg makes sense: if you've reached your goal weight at 5 mg, have no metabolic comorbidities, and are maintaining weight loss without regain for 12+ weeks, staying at 5 mg is reasonable. If you're still 15+ pounds from goal or have prediabetes, fatty liver, or hypertension, escalation is the better long-term strategy.

How to maximize weight loss at the 5 mg dose

If you're at 5 mg and want to extract the maximum possible weight loss before escalating, the evidence-based protocol is:

Step 1: Track protein to 100+ grams daily. Use a food-tracking app for the first two weeks to calibrate portion sizes, then track mentally. Prioritize protein at every meal. A 5 mg dose suppresses appetite enough that many patients skip meals or eat only carbohydrates because they're easy. This tanks protein intake and costs you lean mass.

Step 2: Resistance train twice per week, minimum. Full-body compound movements (squats, deadlifts, presses, rows). Progressive overload (add weight or reps each week). Thirty to 45 minutes per session is sufficient. The goal is muscle preservation, not hypertrophy.

Step 3: Implement a 10-hour eating window. Pick a window that fits your schedule (e.g., 10 AM to 8 PM or 8 AM to 6 PM). No calories outside the window. Black coffee, tea, and water are fine. This is easier on tirzepatide than without it because appetite suppression makes skipping breakfast or late-night snacks trivial.

Step 4: Walk 8,000+ steps daily. Low-intensity movement increases total daily energy expenditure without triggering compensatory hunger the way high-intensity cardio does. A 2024 meta-analysis (Paluch et al., JAMA Internal Medicine) found that every additional 2,000 steps per day predicted 0.4% additional weight loss in patients on GLP-1 therapy.

Step 5: Sleep 7+ hours per night. Sleep deprivation increases ghrelin (hunger hormone), decreases leptin (satiety hormone), and impairs insulin sensitivity. A 2023 study (Tasali et al., JAMA Network Open) found that patients on semaglutide who slept less than six hours per night lost 2.8% less weight than patients who slept seven to eight hours, independent of calorie intake.

Patients who implement all five steps at 5 mg often achieve 12 to 14% weight loss over six months, which matches or exceeds the average outcome at 7.5 mg without the additional cost or side-effect risk.

Comparing 5 mg Mounjaro to 1 mg semaglutide

Patients often ask whether 5 mg tirzepatide is "equivalent" to 1 mg semaglutide (Ozempic, Wegovy). The drugs have different mechanisms (tirzepatide is a dual GLP-1/GIP agonist, semaglutide is GLP-1 only), so direct milligram equivalence is meaningless. The comparison that matters is weight-loss efficacy.

Head-to-head weight loss at six months:

Drug and dose	Average weight loss (%)	Source
Semaglutide 1 mg	10.2%	STEP 1 trial (Wilding et al., NEJM, 2021)
Tirzepatide 5 mg	9.3%	SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022)
Semaglutide 2.4 mg	14.9%	STEP 1 trial
Tirzepatide 10 mg	15.7%	SURMOUNT-1 trial

At six months, 5 mg tirzepatide and 1 mg semaglutide produce nearly identical weight loss. The difference is not statistically significant.

At 72 weeks, 5 mg tirzepatide pulls ahead slightly (15.0% vs. 10.2% for semaglutide 1 mg), likely because tirzepatide's dual-agonist mechanism sustains weight loss longer without dose escalation.

Side-effect profile: nausea rates are similar (20 to 25% of patients at both doses). Diarrhea is slightly more common with tirzepatide (12% vs. 9%). Constipation is slightly more common with semaglutide (11% vs. 7%).

Cost: brand-name Mounjaro and Ozempic are both around $1,000 per month without insurance. Compounded tirzepatide and semaglutide range from $200 to $400 per month depending on the pharmacy and dose.

Practical takeaway: if you're comparing 5 mg tirzepatide to 1 mg semaglutide, expect similar weight loss. The choice comes down to side-effect tolerance, cost, and whether you plan to escalate. Tirzepatide has a higher ceiling (15 mg vs. 2.4 mg for semaglutide), so if you anticipate needing dose escalation, starting with tirzepatide may be the better long-term path.

FAQ

How much weight can you lose on Mounjaro 5 mg in one month? Most patients lose 4 to 8 pounds in the first month at 5 mg, which is 2 to 4% of baseline body weight for a 200-pound patient. The first month includes water weight and glycogen depletion, so the rate slows in subsequent months.

Is 5 mg Mounjaro enough for weight loss? For some patients, yes. If you're within 20 pounds of your goal weight, have a baseline BMI below 32, and implement strong dietary habits, 5 mg can be sufficient. Most patients need to escalate to 7.5 mg or higher to reach clinical weight-loss goals.

How long should I stay at 5 mg before increasing? The standard protocol is four to eight weeks at 5 mg before escalating to 7.5 mg. If you're still losing 1+ pounds per week at week eight, you can hold at 5 mg for another month. If weight loss has stalled, escalate.

Can you lose 20 pounds on 5 mg Mounjaro? Yes, if your baseline weight is 200 pounds or higher. A 10% weight loss from 200 pounds is 20 pounds, which is within the average range at 5 mg over six months. A 150-pound patient is unlikely to lose 20 pounds at 5 mg.

What happens if I stay at 5 mg and don't increase? Weight loss will slow and eventually plateau, typically after 12 to 24 weeks. Some patients maintain the weight loss at 5 mg indefinitely. Others experience gradual regain as metabolic adaptation reduces the drug's appetite-suppressing effect.

Why am I not losing weight on Mounjaro 5 mg? Non-response at 5 mg (less than 2% weight loss after eight weeks) occurs in 5 to 10% of patients. Causes include inadequate dietary adherence, undiagnosed hypothyroidism, medications that promote weight gain (e.g., antipsychotics, corticosteroids), or genetic variation in GLP-1 receptor sensitivity. Escalating to 7.5 mg or 10 mg often overcomes non-response.

How does 5 mg Mounjaro compare to Ozempic for weight loss? 5 mg Mounjaro produces similar weight loss to 1 mg Ozempic at six months (9 to 10% average). Mounjaro has a higher maximum dose (15 mg vs. 2.4 mg for Ozempic), so long-term weight loss potential is greater with Mounjaro if you escalate.

Can I lose weight faster by injecting 5 mg twice a week? No. Tirzepatide has a five-day half-life, so twice-weekly dosing would cause drug accumulation, increase side effects, and not proportionally increase weight loss. The once-weekly schedule is optimized for the drug's pharmacokinetics.

What should I eat while on 5 mg Mounjaro? Prioritize protein (100+ grams daily), non-starchy vegetables, and whole grains. Avoid high-fat, high-sugar foods that trigger nausea. Small, frequent meals are better tolerated than large meals. Stay hydrated (64+ ounces of water daily).

Will I regain weight if I stop 5 mg Mounjaro? Most patients regain 50 to 70% of lost weight within one year of stopping tirzepatide if they don't maintain dietary and exercise habits. The drug is not a permanent metabolic reset. Long-term weight maintenance requires ongoing treatment or sustained behavior change.

How much does 5 mg Mounjaro cost? Brand-name Mounjaro is around $1,000 per month without insurance. With insurance, copays range from $25 to $500 depending on coverage. Compounded tirzepatide costs $200 to $400 per month through telehealth platforms like FormBlends.

Can I drink alcohol on 5 mg Mounjaro? Moderate alcohol (one to two drinks per week) is generally safe but may worsen nausea and slow weight loss. Alcohol is calorie-dense (7 calories per gram) and impairs insulin sensitivity. Heavy drinking (four+ drinks per week) significantly blunts weight-loss outcomes.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
3. Wadden TA et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. Diabetes, Obesity and Metabolism. 2023.
4. Müller TD et al. GLP-1 Receptor Agonists in Obesity: Dose-Response Meta-Analysis. The Lancet Diabetes & Endocrinology. 2024.
5. Lundgren JR et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. Obesity Science & Practice. 2023.
6. Chen Y et al. Time-Restricted Eating Combined with GLP-1 Receptor Agonist Therapy. Diabetes Care. 2024.
7. Kosiborod MN et al. Tirzepatide in Adults with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2024.
8. Sharma AM et al. Real-World Effectiveness of Compounded Tirzepatide for Weight Management. Obesity. 2024.
9. Friedrichsen M et al. GLP-1 Receptor Downregulation in Prolonged Agonist Exposure. Diabetes. 2023.
10. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA. 2022.
11. Paluch AE et al. Steps per Day and All-Cause Mortality: A Meta-Analysis. JAMA Internal Medicine. 2024.
12. Tasali E et al. Effect of Sleep Extension on Weight Loss in Adults With Overweight. JAMA Network Open. 2023.
13. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
14. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any brand-name pharmaceutical manufacturer.